CN104010656B - 使用免疫球蛋白和c1-抑制剂的联合疗法 - Google Patents

使用免疫球蛋白和c1-抑制剂的联合疗法 Download PDF

Info

Publication number
CN104010656B
CN104010656B CN201280046349.8A CN201280046349A CN104010656B CN 104010656 B CN104010656 B CN 104010656B CN 201280046349 A CN201280046349 A CN 201280046349A CN 104010656 B CN104010656 B CN 104010656B
Authority
CN
China
Prior art keywords
inh
immunoglobulin
ivig
compositions
gives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280046349.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104010656A (zh
Inventor
M·巴斯塔
陈新志
M·马特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Original Assignee
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland, US Department of Health and Human Services filed Critical CSL Behring GmbH Deutschland
Publication of CN104010656A publication Critical patent/CN104010656A/zh
Application granted granted Critical
Publication of CN104010656B publication Critical patent/CN104010656B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280046349.8A 2011-09-24 2012-09-21 使用免疫球蛋白和c1-抑制剂的联合疗法 Active CN104010656B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538832P 2011-09-24 2011-09-24
US61/538,832 2011-09-24
PCT/EP2012/068643 WO2013041677A1 (en) 2011-09-24 2012-09-21 Combination therapy using immunoglobulin and c1-inhibitor

Publications (2)

Publication Number Publication Date
CN104010656A CN104010656A (zh) 2014-08-27
CN104010656B true CN104010656B (zh) 2016-02-24

Family

ID=46881067

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280046349.8A Active CN104010656B (zh) 2011-09-24 2012-09-21 使用免疫球蛋白和c1-抑制剂的联合疗法

Country Status (11)

Country Link
US (1) US10471142B2 (ko)
EP (1) EP2758076B1 (ko)
JP (1) JP6190368B2 (ko)
KR (1) KR101956585B1 (ko)
CN (1) CN104010656B (ko)
AU (1) AU2012311483B2 (ko)
CA (1) CA2848510A1 (ko)
DK (1) DK2758076T3 (ko)
ES (1) ES2714999T3 (ko)
HK (1) HK1200334A1 (ko)
WO (1) WO2013041677A1 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2683397T3 (pl) 2011-03-09 2018-01-31 Csl Behring Gmbh Inhibitory czynnika XII do podawania w zabiegach medycznych obejmujących kontakt z powierzchniami sztucznymi
JP6289511B2 (ja) * 2013-02-28 2018-03-07 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 羊水塞栓の治療剤
EP2964255B1 (en) * 2013-03-08 2020-11-04 CSL Behring GmbH Treatment and prevention of remote ischemia-reperfusion injury
CN111529708A (zh) 2013-03-15 2020-08-14 夏尔维洛药品公司 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法
WO2014182631A1 (en) * 2013-05-06 2014-11-13 Baxter International Inc. Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
CN111388655A (zh) * 2013-11-22 2020-07-10 夏尔维洛药品公司 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法
US20180036394A1 (en) * 2015-02-20 2018-02-08 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
AU2017305856A1 (en) 2016-08-05 2019-03-21 Csl Behring Gmbh Pharmaceutical formulations of C1 esterase inhibitor
WO2022251654A1 (en) * 2021-05-28 2022-12-01 West Virginia University Board of Governors on behalf of West Virginia University Mitoneet ligands for use in protection from tissue ischemic reperfusion injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1750844A (zh) * 2003-02-21 2006-03-22 唐纳士公司 用于预防和治疗与局部缺血－再灌注损伤相关的组织损伤的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009158A (en) * 1934-08-01 1935-07-23 Ophthalmological Foundation In Ophthalmic ergograph
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4227762A1 (de) 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
WO2007073186A2 (en) * 2005-12-21 2007-06-28 Pharming Intellectual Property Bv Use of c1 inhibitor for the prevention of ischemia-reperfusion injury
US20100143325A1 (en) * 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
AR076607A1 (es) 2009-05-27 2011-06-22 Baxter Int Composicion acuosa. metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1750844A (zh) * 2003-02-21 2006-03-22 唐纳士公司 用于预防和治疗与局部缺血－再灌注损伤相关的组织损伤的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neuroprotection in Stroke by Complement Inhibition and Immunoglobulin Therapy;Thiruma V. Arumugama et al.;《Neuroscience》;20090206;第158卷(第3期);1074-1089 *

Also Published As

Publication number Publication date
CN104010656A (zh) 2014-08-27
KR101956585B1 (ko) 2019-03-11
AU2012311483B2 (en) 2016-03-10
AU2012311483A1 (en) 2013-05-16
HK1200334A1 (en) 2015-08-07
EP2758076A1 (en) 2014-07-30
DK2758076T3 (en) 2019-04-01
JP6190368B2 (ja) 2017-08-30
ES2714999T3 (es) 2019-05-31
CA2848510A1 (en) 2013-03-28
KR20140075753A (ko) 2014-06-19
EP2758076B1 (en) 2018-12-12
US10471142B2 (en) 2019-11-12
WO2013041677A1 (en) 2013-03-28
US20140234293A1 (en) 2014-08-21
JP2014526541A (ja) 2014-10-06

Similar Documents

Publication Publication Date Title
CN104010656B (zh) 使用免疫球蛋白和c1-抑制剂的联合疗法
US9006180B2 (en) Methods for treating tourniquet-induced injuries
RU2703903C2 (ru) Местное применение антитела к hsv
CN106062000A (zh) 通过施用il‑4r拮抗剂治疗皮肤感染的方法
US20170266164A1 (en) New methods and uses
JP2015057439A (ja) 組織破壊治療及びその治療に使用するための組成物
Olivieri et al. Refractory vasculitic ulcer of the toe in adolescent suffering from Systemic Lupus Erythematosus treated successfully with hyperbaric oxygen therapy
CN103405751A (zh) 一种具有细胞修复功能的组合物及其制备方法和应用
Khoury et al. Fatal case of protothecosis in a hematopoietic stem cell transplant recipient after infliximab treatment for graft-versus-host disease
Visintini et al. Haemorrhagic cystitis, preventive and treatment interventions in patients undergoing haematopoietic stem cell transplantation: A scoping review
US20160324928A1 (en) Methods for treating blepharitis
WO2015105905A1 (en) Treating gingivostomatitis and demodectic mange
Afzal et al. A case report of necrotizing fasciitis managed with the application of negative pressure wound therapy to achieve better wound closure
TWI548415B (zh) 狗圍肛腺瘤之治療方法
Isoa Current trends in the management of sickle cell disease: an overview
RU2370263C2 (ru) Способ детоксикации организма в хирургии инвазивного рака мочевого пузыря
US10842819B2 (en) Compositions and methods for treating itching, gingivostomatitis, and demodectic mange
US20130121982A1 (en) Antidote to the bite of venomous snakes
Lei Inhibition of Panx1 reduces neuroinflammatory response and alleviates brain damage in septic mice
RU2220720C1 (ru) Способ профилактики нарушений овариально-менструального цикла и эндокринного бесплодия у женщин репродуктивного возраста с клещевыми нейроинфекциями
CN116063488A (zh) 一种单克隆抗体及其治疗痛风的用途
TW202002954A (zh) 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法
CN117100862A (zh) Mif和ripk1在围术期缺血性脑损伤中的应用
NO320611B1 (no) Anvendelse av komponent B for fremstilling av et medikament som kan benyttes som cicatrisant og ved behandling av sar.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant